Kymera Therapeutics, Inc. - COMMON STOCK (KYMR)

Historical Holders from Q3 2020 to Q3 2025

Symbol
KYMR on Nasdaq
CUSIP
501575104
Type / Class
Equity / COMMON STOCK
Shares outstanding
71.8M
All holders as of September 30, 2025
Q3 2025
Total 13F shares, excl. options
80.9M
Holdings value
$4.58B
% of all portfolios
0.003%
Grand Portfolio weight change
+0%
Number of holders
205
Number of buys
115
Number of sells
-90
Average Value change %
0%
Average buys %
+0.001%
Average sells %
-0.001%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Kymera Therapeutics, Inc. - COMMON STOCK (KYMR)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BAKER BROS. ADVISORS LP 9.5% $214M 6.67M Baker Bros. Advisors LP Jun 26, 2025
FMR LLC 8.2% +20% $333M $83.2M 5.88M +33.3% FMR LLC Sep 30, 2025
WELLINGTON MANAGEMENT GROUP LLP 7.7% -16.7% $234M -$27.3M 5.37M -10.4% Wellington Management Group LLP Jun 30, 2025
VANGUARD GROUP INC 8.05% $117M 5.23M The Vanguard Group Mar 31, 2025
PRICE T ROWE ASSOCIATES INC /MD/ 7.1% $289M 5.1M T. Rowe Price Associates, Inc. Sep 30, 2025
BlackRock, Inc. 5.4% $122M 3.8M BlackRock, Inc. Jun 30, 2025

Institutional Holders of Kymera Therapeutics, Inc. - COMMON STOCK (KYMR)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 80.9M $4.58B +$140M $56.60 205
2025 Q2 78.8M $3.44B +$271M $43.64 209
2025 Q1 72.8M $2B +$5.35M $27.37 171
2024 Q4 71.7M $2.89B +$18.6M $40.23 177
2024 Q3 69M $3.26B -$2.27M $47.33 173
2024 Q2 67.4M $2.01B +$10.1M $29.85 153
2024 Q1 67.1M $2.7B +$296M $40.20 159
2023 Q4 225K $5.76M +$3.18M $25.46 4
2023 Q3 57.2M $795M -$17.6M $13.90 118
2023 Q2 58M $1.33B +$24.1M $22.99 121
2023 Q1 56.8M $1.68B +$23.2M $29.63 121
2022 Q4 56.1M $1.4B +$97.8M $24.96 114
2022 Q3 51M $1.11B +$28M $21.77 114
2022 Q2 49.2M $969M +$11.5M $19.69 97
2022 Q1 45.3M $1.92B +$61.7M $42.32 124
2021 Q4 43.1M $2.74B +$117M $63.49 122
2021 Q3 34.3M $2.01B +$486M $58.74 113
2021 Q2 26.5M $1.29B +$190M $48.50 109
2021 Q1 22.8M $887M +$90.2M $38.86 94
2020 Q4 20M $1.23B +$52.3M $62.00 72
2020 Q3 16.4M $527M +$527M $32.31 50